We are an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine, consumer care products, supplements and medical devices to improve men’s and women’s health and vitality. Our products currently focus in six main categories including sexual health, pain management, general muscle health, respiratory, sleep, and diabetic care. We deliver innovative and unique health solutions of OTC medicines, devices, consumer and health products, and clinical supplements through four general channels including Direct to Consumer Marketing, E-Commerce, Retail/Wholesale, and International Distribution. Collectively these channels make up our proprietary Beyond Human® Sales & Marketing Platform which was acquired in 2016 and significantly expanded through the development of proprietary algorithms to target consumers and improve efficiency and return in 2018. We are dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products, supplements and medical devices. We are actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC. These “Rx-to-OTC switches” require Food and Drug Administration (“FDA”) approval through a process initiated by the New Drug Application (“NDA”) holder.
Company profile
Website
CEO
Bassam B. Damaj
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
North Horizon, Inc.
SEC CIK
Corporate docs
IRS number
870324697
Latest filings (excl ownership)
15-12G
Securities registration termination
26 Feb 20
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Feb 20
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Feb 20
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Feb 20
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Feb 20
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Feb 20
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Feb 20
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Feb 20
8-K
Submission of Matters to a Vote of Security Holders
14 Feb 20
8-K
Completion of Acquisition or Disposition of Assets
14 Feb 20
Latest ownership filings
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|